GlassScriptPhysician profile
Osama Kandalaft
NPI 1063868065
$5,918.84
in general payments reported to CMS, 2019-2025
30 companies · $16.47 in 2025
The $16.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $718 · 2023: $2,974 · 2024: $2,210 · 2025: $16.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102 · Education: $98.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,101.98 |
| Education | $98.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,128.73 | 2022-2024 | |
| Glaxosmithkline, LLC. | $778.89 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $568.87 | 2022-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $438.81 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $406.10 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $328.03 | 2022-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $282.66 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $279.38 | 2022-2024 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.40 | 2022-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $212.82 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $164.98 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $151.70 | 2022-2023 | Belsomra, Segluromet, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.12 | 2023-2024 | Jardiance, Ofev |
| Pfizer INC. | $107.58 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $104.77 | 2024 | Uptravi, Opsumit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $102.12 | 2022-2024 | Glassia |
| Sunovion Pharmaceuticals INC. | $87.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $70.46 | 2022 | |
| Indivior INC. | $59.78 | 2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.69 | 2023-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $40.04 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $35.30 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $29.57 | 2023 | Auvelity |
| Braeburn INC. | $25.26 | 2024 | Brixadi |
| Watermark Medical, INC. | $19.68 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.25 | 2024 | Givlaari |
| Antares Pharma, INC. | $16.47 | 2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $15.21 | 2023 | Invega Sustenna |
| Seqirus USA INC | $14.78 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Philips North America LLC | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Kandalaft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.